<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="correction" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1505626</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1505626</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review</article-title>
<alt-title alt-title-type="left-running-head">van Riel et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1505626">10.3389/fphar.2024.1505626</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>van Riel</surname>
<given-names>C. A. M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2626762/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Michielsens</surname>
<given-names>C. A. J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Muijen</surname>
<given-names>M. E.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van der Schoot</surname>
<given-names>L. S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van den Reek</surname>
<given-names>J. M. P. A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Jong</surname>
<given-names>E. M. G. J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Radboud University Medical Centre</institution>, <addr-line>Nijmegen</addr-line>, <country>Netherlands</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Dermatology</institution>, <institution>Radboud University Medical Centre</institution>, <addr-line>Nijmegen</addr-line>, <addr-line>Gelderland</addr-line>, <country>Netherlands</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Maastricht University Medical Centre</institution>, <addr-line>Maastricht</addr-line>, <addr-line>Limburg</addr-line>, <country>Netherlands</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Dermatology</institution>, <institution>Faculty of Health</institution>, <institution>Medicine and Life Sciences</institution>, <institution>Maastricht University</institution>, <addr-line>Maastricht</addr-line>, <addr-line>Netherlands</addr-line>, <country>Netherlands</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Radboud University</institution>, <addr-line>Nijmegen</addr-line>, <addr-line>Gelderland</addr-line>, <country>Netherlands</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Approved by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/20178/overview">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: C. A. M. van Riel, <email>charlotte.vanriel@radboudumc.nl</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1505626</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 van Riel, Michielsens, van Muijen, van der Schoot, van den Reek and de Jong.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>van Riel, Michielsens, van Muijen, van der Schoot, van den Reek and de Jong</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front. Pharmacol." journal-id-type="nlm-ta" xlink:href="10.3389/fphar.2024.1369805" ext-link-type="doi">A Corrigendum on <article-title>Dose reduction of biologics in patients with plaque psoriasis: a review</article-title> by van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA and de Jong EMGJ (2024). Front. Pharmacol. 15:1369805. doi: <object-id>10.3389/fphar.2024.1369805</object-id>
</related-article>
<kwd-group>
<kwd>psoriasis</kwd>
<kwd>dose reduction</kwd>
<kwd>dose tapering</kwd>
<kwd>clinical practice</kwd>
<kwd>implementation</kwd>
<kwd>biologics</kwd>
<kwd>biologicals</kwd>
<kwd>(cost-)effectiveness</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Drugs Outcomes Research and Policies</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the published article, there was an error. The symbol &#x2018;&#x2264;&#x2019;, in the phrase &#x201c;[&#x2026;] biologic use for &#x2264;6&#xa0;months [&#x2026;]&#x201d; is incorrect. This should be the symbol &#x2018;&#x2265;&#x2019;.</p>
<p>A correction has been made to the <bold>Discussion</bold>, Paragraph 1. This sentence previously stated:</p>
<p>&#x201c;Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for &#x2264;6&#xa0;months, a stable low disease activity from &#x2265;6&#xa0;months to &#x2265;1&#xa0;year, determined by an absolute or relative PASI (PASI &#x2264;3/&#x2264;5/PASI 75&#x2013;100) and/or DLQI &#x2264;3/&#x2264;5, or BSA &#x2264;1/&#x2264;2, or PGA &#x2264;1/0-2 during a period ranging from 12&#xa0;weeks to &#x2265;1&#xa0;year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023).&#x201d;</p>
<p>The corrected sentence appears below:</p>
<p>&#x201c;Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for &#x2265;6&#xa0;months, a stable low disease activity from &#x2265;6&#xa0;months to &#x2265;1&#xa0;year, determined by an absolute or relative PASI (PASI &#x2264;3/&#x2264;5/PASI 75&#x2013;100) and/or DLQI &#x2264;3/&#x2264;5, or BSA &#x2264;1/&#x2264;2, or PGA &#x2264;1/0-2 during a period ranging from 12&#xa0;weeks to &#x2265;1&#xa0;year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023).&#x201d;</p>
<p>The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.</p>
</body>
<back>
<sec sec-type="disclaimer" id="s1">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>